Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis
The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Purpose The effect of the sodium-glucose 2 (SGLT-2) inhibitors on microvascular complications remains uncertain. We performed a systematic review to determine the efficacy of the SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes. Methods A comprehensive search was performed using Ovid, MEDLINE, EMBASE, Web of Science, and Scopus from inception to May 2019. Randomized trials comparing SGLT-2 inhibitors with placebo or other medication for type 2 diabetes for ≥ 4 weeks were included. Diabetes-related microvascular complications such as nephropathy, retinopathy, neuropathy, and peripheral vascular disease were evaluated. A random-effect model using mean differences for continuous outcomes and risk ratio for dichotomous outcomes was used to synthesize data. PROSPERO (CRD 42017076460). Results A total of 40 RCTs with overall moderate quality of evidence were included. SGLT-2 inhibitors reduced the risk of renal-replacement therapy (0.65; 95% CI 0.54-0.79), renal death (0.57; 95% CI 0.49-0.65), and progression of albuminuria (0.69; 95% CI 0.66-0.73). Conversely, they appeared ineffective in maintaining eGFR (0.33; 95% CI - 0.74 to 1.41) or reducing serum creatinine (- 0.07; 95% CI - 0.26 to 0.11), whereas urine albumin-creatinine ratio (- 23.4; 95% CI - 44.6 to - 2.2) was reduced. Risk of amputation was non-significant (1.30; 95% CI 0.93-1.83). No available data were found regarding neuropathy and retinopathy to perform a quantitative analysis. Conclusion…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While early studies brought attention to several safety areas of interest (acute kidney injury, dehydration, orthostatic hypotension, amputation, and fractures) (5,6), longer-term studies that have prospectively assessed and monitored these events (160,161) have not seen a signi fi cant imbalance in risks.”
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections
King, H., Aubert, R. E., & Herman, W. H. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1414 · Cited by 6,311 · cited 1×
“Reducing the risk of microvascularcomplications is, therefore, an important goal of diabetes care [5].”
BackgroundCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Microvascular and Macrovascular Complications of Diabetes
Fowler, M. J. (2008) · Clinical Diabetes · doi:10.2337/diaclin.26.2.77 · Cited by 1,954
Users' guides to the medical literature : a manual for evidence-based clinical practice
Guyatt, G. H., Rennie, D., Meade, M. O., & Cook, D. J. (2002) · Cited by 1,196
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Erpeldinger, S., Wright, J. M., Gueyffier, F., & Cornu, C. (2011) · BMJ · doi:10.1136/bmj.d4169 · Cited by 803
6. Glycemic Targets: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s006 · Cited by 762
Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 716
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
Glomerular hyperfiltration: definitions, mechanisms and clinical implications
Helal, I., Fick-Brosnahan, G. M., Reed-Gitomer, B., & Schrier, R. W. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.19 · Cited by 673
Kuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0165 · Cited by 662
Kohan, D. E., Fioretto, P., Tang, W., & List, J. F. (2014) · Kidney International · doi:10.1038/ki.2013.356 · Cited by 652
Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70208-0 · Cited by 574
Lavalle-González, F. J., Januszewicz, A., Davidson, J., Tong, C., Qiu, R., Canovatchel, W., & Meininger, G. (2013) · Diabetologia · doi:10.1007/s00125-013-3039-1 · Cited by 492
Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic)
McGinn, T. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1031981 · Cited by 482
Wu, J. H. Y., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., & Neal, B. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00052-8 · Cited by 474
Murad, M. H., Montori, V. M., Ioannidis, J. P. A., Jaeschke, R., Devereaux, P. J., Prasad, K., Neumann, I., Carrasco-Labra, A., Agoritsas, T., Hatala, R., et al. (2014) · JAMA · doi:10.1001/jama.2014.5559 · Cited by 454
Self-citationRoden, M., Weng, J., Eilbracht, J., Delafont, B., Kim, G., Woerle, H. J., & Broedl, U. C. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70084-6 · Cited by 450
Rosenstock, J., Vico, M., Wei, L., Salsali, A., & List, J. F. (2012) · Diabetes Care · doi:10.2337/dc11-1693 · Cited by 408
Shimizu, M., Suzuki, K., Kato, K., Jojima, T., Iijima, T., Murohisa, T., Iijima, M., Takekawa, H., Usui, I., Hiraishi, H., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13520 · Cited by 390
Cherney, D. Z. I., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., von Eynatten, M., & Wanner, C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30182-1 · Cited by 383
Microvascular complications of impaired glucose tolerance
Singleton, J. R., Smith, A. G., Russell, J. W., & Feldman, E. L. (2003) · Diabetes · doi:10.2337/diabetes.52.12.2867 · Cited by 372 · cited 1×
“Diabetes remains a leading cause of blindness, end-stage renal disease, clinical neuropathy and amputations [3, 4].”
BackgroundBailey, C. J., Gross, J. L., Hennicken, D., Iqbal, N., Mansfield, T. A., & List, J. F. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-43 · Cited by 352
SGLT2 Inhibitors and the Diabetic Kidney
Fioretto, P., Zambon, A., Rossato, M., Busetto, L., & Vettor, R. (2016) · Diabetes Care · doi:10.2337/dcs15-3006 · Cited by 348
Users’ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice
Kleinbart, J., & Williams, M. V. (2002) · Evidence Based Mental Health · doi:10.1136/ebmh.5.4.103 · Cited by 345 · cited 2×
“Onepossibility is that the latter result came about by chance or bias perhaps associated with the lack of blind adjudication of outcomes or the unintended effects of other diabetes agents used to different extents in the control and intervention arms [33, 34].”
BackgroundWilding, J. P. H., Charpentier, G., Hollander, P., González‐Gálvez, G., Mathieu, C., Vercruysse, F., Usiskin, K., Law, G., Black, S., Canovatchel, W., et al. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12322 · Cited by 317
DeFronzo, R. A., Lewin, A., Patel, S., Liu, D., Kaste, R., Woerle, H. J., & Broedl, U. C. (2015) · Diabetes Care · doi:10.2337/dc14-2364 · Cited by 296
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., Davidson, M. B., Einhorn, D., Timothy Garvey, W., et al. (2013) · Endocrine Practice · doi:10.4158/ep13176.cs · Cited by 280
Ito, D., Shimizu, S., Inoue, K., Saito, D., Yanagisawa, M., Inukai, K., Akiyama, Y., Morimoto, Y., Noda, M., & Shimada, A. (2017) · Diabetes Care · doi:10.2337/dc17-0518 · Cited by 279
Puckrin, R., Saltiel, M.-P., Reynier, P., Azoulay, L., Yu, O. H. Y., & Filion, K. B. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1116-0 · Cited by 278
The burden of type 2 diabetes: are we doing enough?
Zimmet, P. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(03)72783-9 · Cited by 260 · cited 1×
“, retinopathy, nephropathy, and neuropathy, impair the quality of life of patients with type 2 diabetes and increase the cost of care [1, 2].”
BackgroundForst, T., Guthrie, R., Goldenberg, R., Yee, J., Vijapurkar, U., Meininger, G., & Stein, P. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12273 · Cited by 255
Rosenstock, J., Jelaska, A., Zeller, C., Kim, G., Broedl, U. C., Woerle, H. J., & on behalf of the EMPA‐REG BASAL trial investigators (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12503 · Cited by 252
Sano, M., Takei, M., Shiraishi, Y., & Suzuki, Y. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2760w · Cited by 252
US public health and the 21st century: diabetes mellitus
McKinlay, J., & Marceau, L. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02641-6 · Cited by 201
Hayashi, T., Fukui, T., Nakanishi, N., Yamamoto, S., Tomoyasu, M., Osamura, A., Ohara, M., Yamamoto, T., Ito, Y., & Hirano, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0491-5 · Cited by 196
Fioretto, P., Del Prato, S., Buse, J. B., Goldenberg, R., Giorgino, F., Reyner, D., Langkilde, A. M., Sjöström, C. D., Sartipy, P., & On Behalf of the DERIVE Study Investigators (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13413 · Cited by 195
Scheen, A. J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0264-4 · Cited by 182
Rodríguez-Gutiérrez, R., & Montori, V. M. (2016) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.002901 · Cited by 176
Self-citationCherney, D., Lund, S. S., Perkins, B. A., Groop, P.-H., Cooper, M. E., Kaspers, S., Pfarr, E., Woerle, H. J., & von Eynatten, M. (2016) · Diabetologia · doi:10.1007/s00125-016-4008-2 · Cited by 174
SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
Kawanami, D., Matoba, K., Takeda, Y., Nagai, Y., Akamine, T., Yokota, T., Sango, K., & Utsunomiya, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051083 · Cited by 168
Dagogo‐Jack, S., Liu, J., Eldor, R., Amorin, G., Johnson, J., Hille, D., Liao, Y., Huyck, S., Golm, G., Terra, S. G., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13116 · Cited by 156
Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics
Wolkow, P. P., Niewczas, M. A., Perkins, B., Ficociello, L. H., Lipinski, B., Warram, J. H., & Krolewski, A. S. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050556 · Cited by 155
Ott, C., Jumar, A., Striepe, K., Friedrich, S., Karg, M. V., Bramlage, P., & Schmieder, R. E. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0510-1 · Cited by 149
Grunberger, G., Camp, S., Johnson, J., Huyck, S., Terra, S. G., Mancuso, J. P., Jiang, Z. W., Golm, G., Engel, S. S., & Lauring, B. (2018) · Diabetes Therapy · doi:10.1007/s13300-017-0337-5 · Cited by 148
Terra, S. G., Focht, K., Davies, M., Frias, J., Derosa, G., Darekar, A., Golm, G., Johnson, J., Saur, D., Lauring, B., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12888 · Cited by 147
Yang, X., Lai, D., Zhong, X., Shen, H., & Huang, Y. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1730-x · Cited by 134
Søfteland, E., Meier, J. J., Vangen, B., Toorawa, R., Maldonado-Lutomirsky, M., & Broedl, U. C. (2017) · Diabetes Care · doi:10.2337/dc16-1347 · Cited by 128
Kovács, C. S., Seshiah, V., Merker, L., Christiansen, A. V., Roux, F., Salsali, A., Kim, G., Stella, P., Woerle, H., & Broedl, U. C. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.05.511 · Cited by 122
Hollander, P., Liu, J., Hill, J., Johnson, J., Jiang, Z. W., Golm, G., Huyck, S., Terra, S. G., Mancuso, J. P., Engel, S. S., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-017-0354-4 · Cited by 107
Aronson, R., Frias, J., Goldman, A., Darekar, A., Lauring, B., & Terra, S. G. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13251 · Cited by 98
Jabbour, S. A., Frías, J. P., Hardy, E., Ahmed, A., Wang, H., Öhman, P., & Guja, C. (2018) · Diabetes Care · doi:10.2337/dc18-0680 · Cited by 97
Dziuba, J., Alperin, P., Racketa, J., Iloeje, U., Goswami, D., Hardy, E., Perlstein, I., Grossman, H. L., & Cohen, M. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12261 · Cited by 96
New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
Dekkers, C. C. J., Gansevoort, R. T., & Heerspink, H. J. L. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-0992-6 · Cited by 82
Lu, C., Min, K. W., Chuang, L., Kokubo, S., Yoshida, S., & Cha, B. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12422 · Cited by 66
Clinical Pharmacology: Advances and Applications
(2020) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa · Cited by 63
Yang, W., Ma, J., Li, Y., Li, Y., Zhou, Z., Kim, J. H., Zhao, J., & Ptaszynska, A. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12634 · Cited by 58
Takashima, H., Yoshida, Y., Nagura, C., Furukawa, T., Tei, R., Maruyama, T., Maruyama, N., & Abe, M. (2018) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118782872 · Cited by 56
Perna, S., Mainardi, M., Astrone, P., Gozzer, C., Biava, A., Bacchio, R., Spadaccini, D., Solerte, S. B., & Rondanelli, M. (2018) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s164785 · Cited by 54
Devineni, D., Curtin, C. R., Marbury, T. C., Smith, W. B., Vaccaro, N. M., Wexler, D. B., Vandebosch, A., Rusch, S., Stieltjes, H., & Wajs, E. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.12.013 · Cited by 51
Ridderstråle, M., Rosenstock, J., Andersen, K. R., Woerle, H. J., Salsali, A., & on behalf of the EMPA‐REG H2H‐SU trial investigators (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13457 · Cited by 51
Nomoto, H., Miyoshi, H., Sugawara, H., Ono, K., Yanagiya, S., Oita, M., Nakamura, A., & Atsumi, T. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0255-8 · Cited by 46
Han, K. A., Chon, S., Chung, C. H., Lim, S. K., Lee, K. W., Baik, S.-H., Jung, C. H., Kim, D. S., Park, K. S., Yoon, K., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13394 · Cited by 45
Kario, K., Hoshide, S., Okawara, Y., Tomitani, N., Yamauchi, K., Ohbayashi, H., Itabashi, N., Matsumoto, Y., & Kanegae, H. (2018) · The Journal of Clinical Hypertension · doi:10.1111/jch.13367 · Cited by 42
Araki, E., Onishi, Y., Asano, M., Kim, H., & Yajima, T. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12853 · Cited by 38
Hattori, S. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12781 · Cited by 37
Urinary inflammatory cytokines as indicators of kidney damage in type 2 diabetic patients
Sangoi, M. B., de Carvalho, J. A. M., Tatsch, E., Hausen, B. S., Bollick, Y. S., Londero, S. W. K., Duarte, T., Scolari, R., Duarte, M. M. M. F., Premaor, M. O., et al. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.06.028 · Cited by 30
Pace, D. J., Dukleska, K., Phillips, S. M., Gleason, V. M., & Yeo, C. J. (2018) · Journal of Pancreatic Cancer · doi:10.1089/pancan.2018.0016 · Cited by 28
Cho, K. Y., Nakamura, A., Omori, K., Takase, T., Miya, A., Manda, N., Kurihara, Y., Aoki, S., Atsumi, T., & Miyoshi, H. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13557 · Cited by 19
Suzuki, K., Mitsuma, Y., Sato, T., 安楽, 匠., & Hatta, M. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2741w · Cited by 17
SGLT2 inhibitors in the real world: too good to be true?
FITCHETT, D. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30259-0 · Cited by 9 · cited 1×
“These agents have been shown to reduce the risk of macrovascular patient-important outcomes [31], although these results have been questioned [32].”
Dorsey-Treviño, E. G., Contreras-Garza, B. M., González‐González, J. G., Álvarez‐Villalobos, N. A., Salcido‐Montenegro, A., González-Colmenero, A. D., Farrell, A. M., González‐Nava, V., Rodriguez‐Tamez, G., Montori, V. M., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020692 · Cited by 4
Self-citationCoca, S. G., Ismail-Beigi, F., Haq, N., Krumholz, H. M., & Parikh, C. R. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.2230 · Cited by 1
Research works printed but not linked: 1
- Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration [computer program]. The Netherlands 2014
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Diabetic nephropathy: Focusing on pathological signals, clinical treatment, and dietary regulation
Hu, Q., Chen, Y., Deng, X., Li, Y., Ma, X., Zeng, J., & Zhao, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114252 · Cited by 162
Heyward, J., Mansour, O., Olson, L., Singh, S., & Alexander, G. C. (2020) · PLOS ONE · doi:10.1371/journal.pone.0234065 · Cited by 109
“In additional to the previously referenced meta-analysis [10], two recent meta-analyses of RCTs published in May and September 2019, respectively, found a non-significant increased risk of amputation among three large studies assessing canagliflozin, dapagliflozin, and empagliflozin [45][46].”
ResultEleftheriadou, A., Riley, D., Zhao, S. S., Austin, P., Hernández, G., Lip, G. Y. H., Jackson, T. L., Wilding, J. P. H., & Alam, U. (2024) · Diabetologia · doi:10.1007/s00125-024-06132-5 · Cited by 73
“Additionally, recent studies have suggested a possible role for both GLP1-ra and SGLT2is in the management of diabetic retinopathy and DMO that extends beyond glycaemic control [10, 11].”
Background
Metadata
- Authors
- Dorsey-Treviño, E. G., González-González, J. G., Alvarez-Villalobos, N., González-Nava, V., Contreras-Garza, B. M., Díaz González-Colmenero, A., Rodríguez-Tamez, G., Barrera-Flores, F. J., Farrell, A. M., Montori, V. M., & Rodriguez-Gutierrez, R.
- Affiliations
- Universidad Autónoma de Nuevo León (MX)
- Mayo Clinic (US)
- Venue
- Journal of Endocrinological Investigation
- Published
- 2019-09-05
- Volume
- 43
- Issue
- 3
- Pages
- 289-304
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- OpenAlex
- W2972290078
- Cited by
- 39
- References
- 81
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 5 · 2023: 6 · 2022: 8 · 2021: 7 · 2020: 5
- FWCI
- 0.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Journal of Endocrinological Investigation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mayo Clinic
- Universidad de León
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- SGLT2 inhibitors, type 2 diabetes, microvascular complications, diabetic nephropathy, renal replacement therapy, renal death, albuminuria, estimated glomerular filtration rate, serum creatinine, diabetic retinopathy, diabetic neuropathy, peripheral vascular disease, amputation risk
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Humans, Hypoglycemic Agents, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.